Cat. No.: HY-18964

MG-101

Name: MG-101
Brand: MedChemExpress
SKU: HY-18964
Price: 60.00 USD
Availability: InStock
Rating: 5 (13 reviews)

(Synonyms: Calpain inhibitor I; Ac-LLnL-CHO; ALLN)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

MG-101 (ALLN) is an inhibitor of cysteine proteases which inhibits calpain I, calpain II, cathepsin B and cathepsin L with K_is of 190, 220, 150 and 500 pM, respectively. MG-101 induces apoptosis and inhibits tumor growth, it can be used for the research of colon cancer.

For research use only. We do not sell to patients.

Purity : 98.0%
CAS No.: 110044-82-1
Formula: C₂₀H₃₇N₃O₄
Molecular Weight:383.53

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MG-101 Chemical Structure

CAS No.: 110044-82-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Protocols (8)
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
B16	IC₅₀	14.5 μM Compound: ALLN	Inhibitory concentration of the compound was determined against melanoma B16 cells Inhibitory concentration of the compound was determined against melanoma B16 cells	[PMID: 15634028]
HeLa	CC₅₀	25.1 μM Compound: ALLN	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 23357632]
L1210	IC₅₀	3 μM Compound: ALLN	Inhibitory concentration of the compound was determined against L1210 cells Inhibitory concentration of the compound was determined against L1210 cells	[PMID: 15634028]

In Vitro

MG-101 (0-26 μM; 24 h) affects the growth of colon cancer HCT116 cells^[1].
MG-101 (0-26 μM; 24 h) induces apoptosis of various cancer cells^[1].
MG-101 (0-26 μM; 24 h) induces Bax-dependent apoptosis in HCT116 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[1]

View Protocol

Cell Line:

HCT116 cell line
Concentration:

0-26 μM
Incubation Time:

24 hours
Result:

Anchorage-independently and significantly decreased the viability of HCT116 cells.

Western Blot Analysis^[1]

View Protocol

Cell Line:

HCT116, RKO, SW480 and HepG2 cell lines
Concentration:

0-26 μM
Incubation Time:

24 hours
Result:

Dose-dependently decreased the concentration of pro-caspase 3 and increased the concentration of cleaved-PARP in HCT116 cells. Induced apoptosis of HCT116, RKO, SW480 and HepG2 cells.

Western Blot Analysis^[1]

View Protocol

Cell Line:

HCT116, HCT116/p53^-/- and HCT116/Bax^-/- cell lines
Concentration:

0-26 μM
Incubation Time:

24 hours
Result:

Induced apoptosis via a Bax-dependent manner, but not via a p53-dependent manner.

In Vivo

MG-101 (10 mg/kg; i.p. once daily for 15 days) inhibits tumor growth in nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female athymic nude mice with HCT116 cells injection^[1]
Dosage:

10 mg/kg
Administration:

Intraperitoneal injection; 10 mg/kg once daily; for 15 days
Result:

Significantly decreased tumor weight and volume of treated mice at day 26 compared to control mice, and showed no effect on body weights.

Chemical Information

CAS No. 110044-82-1
Appearance Solid
Molecular Weight 383.53
Formula C₂₀H₃₇N₃O₄
Color White to light yellow
SMILES

O=C(N[C@H](C=O)CCCC)[C@@H](NC([C@@H](NC(C)=O)CC(C)C)=O)CC(C)C
Synonyms

Calpain inhibitor I; Ac-LLnL-CHO; ALLN
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (13)

All WBRT-PCRCell Proliferation/Viability AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage. [Abstract]

2025 Dec 17;10(1):413. PMID: 41407678
Science

A structure of human Scap bound to Insig-2 suggests how their interaction is regulated by sterols. [Abstract]

2021 Mar 5;371(6533):eabb2224. PMID: 33446483
Nat Commun

Phenazine biosynthesis-like domain-containing protein (PBLD) and Cedrelone promote antiviral immune response by activating NF-ĸB. [Abstract]

2025 Jan 8;16(1):496. PMID: 39779683

MG-101 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 8;16(1):496. [Abstract]

Real-time PCR analysis the mRNA expression of IFNs and ISGs in PBLD-overexpressing HeLa cells treated with DMSO, MG101 (20 μM) or QNZ (10 μM) or transfected with siNF-κB (10 nM) or siNC, and then infected with BPIV3 (MOI = 1), VSV (MOI = 1) or HSV-1 (MOI = 1), respectively for 24 h.

MG-101 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 8;16(1):496. [Abstract]

To investigate the roles of NF-κB in PBLD mediated IFN-I signaling pathway, we used two pharmacological inhibitors of NF-κB, MG-101 and QNZ. The optimal concentrations of MG-101 (20 μM) and QNZ (10 μM) were determined through cell viability assays.
J Genet Genomics

Yki stability and activity are regulated by Ca2+-calpains axis in Drosophila. [Abstract]

2024 Oct;51(10):1020-1029. PMID: 38663479
Cell Rep

Structural basis for sterol sensing by Scap and Insig. [Abstract]

2021 Jun 29;35(13):109299. PMID: 34192549
Int J Mol Sci

Decreased Expression of Plakophilin-2 and αT-Catenin in Arrhythmogenic Right Ventricular Cardiomyopathy: Potential Markers for Diagnosis. [Abstract]

2022 May 16;23(10):5529. PMID: 35628349

MG-101 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 May 16;23(10):5529. [Abstract]

Protein levels in HL-1/shLuc, shCTNNA3, and shPKP2 cardiomyocytes after MG101 (5 μM, 24 h) treatment.
Glia

Astrocyte-specific loss of lactoferrin influences neuronal structure and function by interfering with cholesterol synthesis. [Abstract]

2022 Dec;70(12):2392-2408. PMID: 35946355
Sci Rep

Substrate profiling of marine-derived thermotolerant cysteine protease reveals unique cleavage preferences for industrial applications. [Abstract]

2025 Jul 21;15(1):26481. PMID: 40691222

MG-101 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Jul 21;15(1):26481. [Abstract]

Dose response curves of two inhibitors, leupeptin and MG101 (0.01 nM-10 μM), against globupain. The substrate Boc-QAR-amc was used. Activity was normalized to a vehicle treated sample.
Sci Rep

Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. [Abstract]

2022 Jul 16;12(1):12197. PMID: 35842458
J Cell Mol Med

Calpain-2 plays a pivotal role in the inhibitory effects of propofol against TNF-α-induced autophagy in mouse hippocampal neurons. [Abstract]

2020 Aug;24(16):9287-9299. PMID: 32627970

MG-101 purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2020 Aug;24(16):9287-9299. [Abstract]

We found that TNF-α-induced calpain activation was attenuated by pre-treatment of neurons with 50 μmol/L calpain inhibitor IV (a calpain-2 selective inhibitor), 200 nmol/L NA101 (a calpain-2 selective inhibitor), 20 μmol/L calpain Inhibitor I (MG-101, a non-selective calpain inhibitor) and 50 μmol/L calpeptin (a non-selective calpain inhibitor).
Exp Cell Res

Cardiac ischemic preconditioning promotes cMyBP-C phosphorylation by inhibiting the calpain-mediated proteolysis. [Abstract]

2023 Dec 15;433(2):113859. PMID: 38000772
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
bioRxiv

2020 Jun.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (260.74 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6074 mL

13.0368 mL

26.0736 mL

5 mM

0.5215 mL

2.6074 mL

5.2147 mL

10 mM

0.2607 mL

1.3037 mL

2.6074 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (4.35 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.67 mg/mL (4.35 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (4.35 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocols

All Cell Biology Animals and Diseases Signal Pathway Related

Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li SZ, et al. ALLN hinders HCT116 tumor growth through Bax-dependent apoptosis. Biochem Biophys Res Commun. 2013 Jul 26;437(2):325-330. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6074 mL	13.0368 mL	26.0736 mL	65.1839 mL
	5 mM	0.5215 mL	2.6074 mL	5.2147 mL	13.0368 mL
	10 mM	0.2607 mL	1.3037 mL	2.6074 mL	6.5184 mL
	15 mM	0.1738 mL	0.8691 mL	1.7382 mL	4.3456 mL
	20 mM	0.1304 mL	0.6518 mL	1.3037 mL	3.2592 mL
	25 mM	0.1043 mL	0.5215 mL	1.0429 mL	2.6074 mL
	30 mM	0.0869 mL	0.4346 mL	0.8691 mL	2.1728 mL
	40 mM	0.0652 mL	0.3259 mL	0.6518 mL	1.6296 mL
	50 mM	0.0521 mL	0.2607 mL	0.5215 mL	1.3037 mL
	60 mM	0.0435 mL	0.2173 mL	0.4346 mL	1.0864 mL
	80 mM	0.0326 mL	0.1630 mL	0.3259 mL	0.8148 mL
	100 mM	0.0261 mL	0.1304 mL	0.2607 mL	0.6518 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MG-101

Publications Citing Use of MedChemExpress (MCE) MG-101